Table 3 Follow-up data on the two patient groups

Effective therapy(n, %)

142 (82.56)

57 (65.52)

<0.001

Cardiac function grade

NYHA I (n, %)

48 (27.91)

18 (20.69)

0.727

NYHA II (n, %)

85 (49.42)

36 (41.38)

0.359

NYHA III (n, %)

33 (19.19)

26 (29.89)

0.274

NYHA IV (n, %)

6 (3.49)

7 (8.05)

0.724

Heart rate(beats/minute)

81.49 ± 13.65

83.49 ± 11.50

0.241

SBP(mmHg)

114.15 ± 13.01

123.31 ± 12.54

<0.001

SDP(mmHg)

70.52 ± 8.53

76.91 ± 12.28

<0.001

LVEF(%)

49.06 ± 9.96

44.05 ± 9.67

0.005

LEVDD(mm)

50.55 ± 9.13

54.60 ± 12.67

0.004

LVESD(mm)

38.46 ± 6.61

42.72 ± 9.04

<0.001

Left atrial size(mm)

44.00 ± 8.54

43.31 ± 8.16

0.533

Cardiac output(L/min)

5.3(4.2, 6.5)

5.3(4.8, 6.4)

0.180

Hemoglobin(g/L)

121.08 ± 16.34

119.39 ± 16.13

0.430

Hematocrit(%)

38.65 ± 5.26

38.22 ± 4.08

0.473

NT-ProBNP(pg/ml)

612.0(399.0, 788.0)

668.0(435.0, 891.5)

0.014

Serum creatinine(umol/L)

75.67 ± 17.14

76.23 ± 17.69

0.807

Alanine aminotransferase(IU/L)

30.40 ± 9.31

30.98 ± 9.89

0.649

Aspartate aminotransferase(IU/L)

31.56 ± 9.38

30.82 ± 9.70

0.550

Blood glucose(mmol/L)

5.21 ± 1.52

5.55 ± 1.61

0.095

Potassium ion(mmol/L)

4.20 ± 0.38

4.21 ± 0.34

0.807

Sodiumion(mmol/L)

139.80 ± 4.55

139.35 ± 4.44

0.452

Liver insufficiency(n, %)

0 (0.00)

0 (0.00)

N/A

Renal insufficiency(n, %)

0 (0.00)

0 (0.00)

N/A

Hyperkalemia(n, %)

0 (0.00)

0 (0.00)

N/A

Symptomatic hypotension(n, %)

0 (0.00)

(0.00)

N/A

Angioedema(n, %)

0 (0.00)

0 (0.00)

N/A

Acute heart failure(n, %)

3 (1.74)

2 (2.30)

0.864

Follow-up death(n, %)

0 (0.00)

0 (0.00)

N/A